NCT02450591View on ClinicalTrials.gov

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

NACompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 14, 2015

Primary Completion Date

December 11, 2017

Study Completion Date

December 11, 2017

Conditions
Oligometastatic Lung Adenocarcinoma
Interventions
DRUG

Erlotinib

OTHER

Local Therapies

Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02450591 - Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations | Biotech Hunter | Biotech Hunter